Ulcerative colitis (UC) is a chronic inflammatory disease of the colon characterized by mucosal ulceration. Various therapeutic antibodies that target TNF agents have drastically changed the therapeutic arsenal for UC. Golimumab, is a novel anti-TNF antibody that represents a new treatment option for patients suffering from moderate to severe UC failing conventional treatment. The current article aims to provide brief information about this drug.
The introduction of therapeutic antibodies against tumor necrosis factor (TNF) had a major impact on the treatment of ulcerative colitis (UC). Infliximab and adalimumab are powerful agents that are used for remission induction and maintenance therapy in UC and have an acceptable safety profile. Although, a proportion of UC patients for whom therapy with anti-TNF agents is indicated fail or become intolerant to treatment with infliximab or…
